Editorial board member Daniel R Ouellette (Wayne State University School of Medicine, Detroit, MI, US) considers what is known to-date about the impact of e-cigarettes or vaping versus traditional tobacco products on respiratory disease.
1. What is the overall effect on respiratory disease of switching from smoking tobacco to vaping? (0:12)
2. What is the effect of e-cigarettes on exacerbations of asthma and COPD? (0:48)
3. What components of e-cigarettes may contribute to a decrease in respiratory health? (1:31)
4. How does the use of e-cigarette use among young people affect their likelihood of later using traditional tobacco products? (2:01)
5. What studies of vaping would you like to see performed in the future? (2:41)
Speaker disclosure: Daniel R Ouellette has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.
Related Videos In COPD
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 1)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. What are the limitations of current pulmonary rehabilitation programmes? (0:05) 2. What are the potential advantages and limitations of tele-rehabilitation? (1:44) Speaker disclosures: Henrik Hansen […]
Henrik Hansen, ERS 2019 – Pulmonary Tele-rehabilitation Versus Conventional Rehabilitation (Part 2)
We met Henrik Hansen, from National University Hospital, Copenhagen, Denmark, at ERS 2019 to discuss his study results – 1-year follow-up of pulmonary tele-rehabilitation versus conventional pulmonary rehabilitation. Questions 1. Could you tell us a little about your recent clinical trial investigating tele-rehabilitation? (0:05) 2. Which patients are most likely to benefit from this approach? […]
Gerard Criner, ERS 2019 – Identification of Patients with COPD who Benefit from Benralizumab
We met with Gerard Criner, of Temple University, at ERS 2019 in Madrid, to discuss his presentation on identification of patients with chronic obstructive pulmonary disease who benefit from benralizumab. Questions 1. What is the mechanism of action of benralizumab? 2. Could you tell us a little about the aims and design of the GALATHEA […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!